NRG1 has been implicated in lapatinib resistance [27] as well as overcoming the inhibitory effect of gefitinib [32] and trastuzumab [33] treatment in HER2-overexpressing breast cancer cells. The gene discussed is ERBB2; the disease is breast cancer.